<u> </u>	Application No.	Applicant(s)
Notice of Allowability	10/089,625	KOO ET AL.
	Examiner	Art Unit
	Deepak R Rao	1624
The MAILING DATE of this communication app All claims being allowable, PROSECUTION ON THE MERITS Is herewith (or previously mailed), a Notice of Allowance (PTOL-88 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT I of the Office or upon petition by the applicant. See 37 CFR 1.37	S (OR REMAINS) CLOSED ir 5) or other appropriate commi RIGHTS. This application is s	n this application. If not included unication will be mailed in due course. THIS
1. This communication is responsive to the communication	filed on December 5, 2003.	
2. ☑ The allowed claim(s) ♣/are <u>1-5 and 8-12</u> .		
3. The drawings filed on are accepted by the Examin	er.	
 4. Acknowledgment is made of a claim for foreign priority of a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have 1. Copies of the certified copies of the priority of 1. Certified copies of the priority of 1. Certified copies not received: 	ve been received. ve been received in Application	on No
Applicant has THREE MONTHS FROM THE "MAILING DATE noted below. Failure to timely comply will result in ABANDON THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		a reply complying with the requirements
5. A SUBSTITUTE OATH OR DECLARATION must be sub- INFORMAL PATENT APPLICATION (PTO-152) which gi		
 6. ☐ CORRECTED DRAWINGS (as "replacement sheets") me (a) ☐ including changes required by the Notice of Draftspe 1) ☐ hereto or 2) ☐ to Paper No./Mail Date 	rson's Patent Drawing Review	v (PTO-948) attached
(b) including changes required by the attached Examine Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR	r's Amendment / Comment or 1.84(c)) should be written on ti	ne drawings in the front (not the back) of
each sheet. Replacement sheet(s) should be labeled as such in 7. DEPOSIT OF and/or INFORMATION about the depattached Examiner's comment regarding REQUIREMENT	osit of BIOLOGICAL MATI	ERIAL must be submitted. Note the
Attachment(s) 1. ☑ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB	6. Interview So	 5. ☐ Notice of Informal Patent Application (PTO-152) 6. ☐ Interview Summary (PTO-413), Paper No./Mail Date 7. ☒ Examiner's Amendment/Comment
Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	Requirement for Deposit 8. Examiner's Statement of Reasons for Allow 9. Other Deepak R Rao Primary Examiner Art Unit: 1624	Deepak R Rao Primary Examiner

Application/Control Number: 10/089,625

Art Unit: 1624

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. John Alexander on March 22, 2004.

The application has been amended as follows:

In claim 1, line 1, delete "derivative of the following formula I1):" and in place insert:

-- compound of the following formula (I): --.

In claim 2, line 1, delete "derivative" and in place insert -- compound --.

In claim 3, line 1, delete "derivative" and in place insert -- compound --.

In claim 4, line 1, delete "derivative" and in place insert -- compound ---.

In claim 4, line 15 (last line), delete "propion)oxy-n-propyl)pyridine-3-sulfonamide;" and

in place insert: -- propion)oxy-n-propyl)pyridine-3-sulfonamide. --

In claim 5, line 1, delete "derivative" and in place insert -- compound --.

Cancel claims 6 and 7 without any prejudice or disclaimer.

In claim 9, line 1, delete "bases" and in place insert -- base --.

Application/Control Number: 10/089,625

Art Unit: 1624

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance:

The closest reference of record, WO 96/12708 teaches pyridine sulfonyl amide urea derivatives, see formula (I) in page 3. The instantly claimed compounds differ from the reference compounds by having a $-C(=O)-(CH_2)_n$ -O-R group (wherein n is 1 to 3), in place of the "R" in formula (I). The reference does not teach or fairly suggest any modification to the reference compounds and therefore, it is deemed that the reference does not provide any motivation to one of ordinary skill in the art to modify the reference compounds to prepare the instantly claimed compounds. Accordingly, the instantly claimed compounds are deemed to be novel and patentably distinct.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Deepak Rao whose telephone number is (571) 272-0672. The examiner can normally be reached on Tuesday-Friday from 6:30am to 5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Mukund Shah, can be reached on (571) 262-0674. If you are unable to reach Dr. Shah within a 24 hour period, please contact James O. Wilson, Acting-SPE of 1624 at (571) 272-

Application/Control Number: 10/089,625

Art Unit: 1624

Page 4

0661. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.

Deepak Rao Primary Examiner Art Unit 1624

March 22, 2004